Beacon Biosignals Raises $11 Million in Series B Funding
Beacon Biosignals has successfully raised $11 million in a Series B funding round dated April 6, 2026. The company, which focuses on advancing brain health through AI-driven neurotechnology, aims to use this capital to further develop its innovative solutions.
Investors Backing the Round
The investment round saw participation from a consortium of investors including JSL Health, Palo Santo VC, Kicker Ventures, and Samsung Next. There was no single lead investor in this round, indicating a collaborative effort to support Beacon Biosignals' mission.
Company Leadership
Beacon Biosignals was co-founded by Jacob Donoghue, MD PhD, who also serves as the CEO, and Jarrett Revels, who is the CTO. Donoghue and Revels have been pivotal in steering the company towards integrating artificial intelligence with neurotechnology to enhance brain health.
Use of Funds
While specific plans for the newly acquired funds were not disclosed, it is expected that Beacon Biosignals will channel this investment towards scaling its AI-driven neurotechnology solutions. This could potentially include expanding their team, enhancing product development, and possibly exploring new markets.
About Beacon Biosignals
Beacon Biosignals is at the forefront of neurotechnology, leveraging artificial intelligence to develop solutions that improve brain health. By integrating AI with neurotechnology, the company aims to address a range of neurological challenges, providing innovative tools for researchers and clinicians.
This latest funding round marks a significant step for Beacon Biosignals as it continues to push the boundaries of what is possible in brain health technology.